In­s­med's an­ti-in­flam­ma­to­ry drug wins break­through sta­tus; Ky­owa Kirin backs new fund from 4BIO Cap­i­tal

→ A mixed mid-stage read­out of In­smed‘s an­ti-in­flam­ma­to­ry drug, INS1007, read more like a win giv­en the low ex­pec­ta­tions for the tri­al back in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.